SCB Perspectives: ISO Publishes Three-Part Documentary Standard on Ancillary Materials for Cell Manufacturing Processes

This blog post was originally shared at standardscoordinatingbody.org. Claudia Zylberberg, SCB Board Member, Akron Biotech December 17, 2018 I’m pleased to announce that one of the first standards advancement projects SCB was involved in, Ancillary Materials Used in Cellular Therapy Production, has culminated in the publication of a three-part documentary ISO standard (ISO/TS 20399): Part

American Society of Hematology Annual Meeting highlights the promise of CAR-T cell therapy

The 60th Annual American Society of Hematology Annual Meeting in San Diego featured a number of presentations that highlighted the promise of CAR-T therapy. Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center reported promising early results from a Phase Ib/II clinical trial that used autologous CAR-T cells to recognize and fight Hodgkin

Court denies University of California appeal, upholding the Broad Institute patents on CRISPR gene editing

The US Court of Appeals for the Federal Circuit upheld a previous decision by the US Patent and Trademark Office which awarded the intellectual property on CRISPR-Cas9 gene editing technology to the Broad Institute of the Massachusetts Institute of Technology and Harvard University, striking down an appeal by University of California, Berkeley and the University

Akron co-sponsors the 11th annual Business of Regenerative Medicine Symposium at the University of Pennsylvania

The 11th annual Business of Regenerative Medicine: Innovation, Clinical Translation, and Entrepreneurship Symposium took place on July 17th-18th. The event was hosted by the Center for Cellular Immunotherapies and the Institute for Regenerative Medicine at the University of Pennsylvania in partnership with Case Western Reserve University, the Harvard Stem Cell Institute, the Parker H. Petit

Developing a manufacturing workforce for the regenerative medicine industry

One of the central challenges facing the regenerative medicine industry today is developing the workforce necessary to produce and commercialize advanced therapies and engineered tissues. The industry needs a well-trained workforce to grow; however, it is difficult to develop a workforce for an emerging industry which has yet to achieve the scale necessary to employ

Akron Biotech participates in the Phacilitate Automation Special Interest Group

Last week, Akron participated in the Phacilitate Automation Special Interest Group, a gathering of key industry stakeholders aimed at fostering discussion around the main challenges associated with developing and implementing automation solutions in an industry characterized by process variety and complexity, as well as the need to ensure data integrity. According to Dr. Rodney Rietze,

Akron Biotech and U.S.-based industry leaders meet with the Argentine regulatory authority (ANMAT) to discuss regulatory developments in regenerative medicine

Last week, the Akron team joined more than 1,600 participants from 50+ countries at the annual meeting of the International Society for Cell and Gene Therapy (ISCT) in Montreal. Chaired by David DiGiusto, PhD (Stanford School of Medicine), Sarah Nikiforow, MD, PhD (Dana Farber Cancer Institute), and Denis-Claude Roy, MD, FRCPC (Hôpital Maisonneuve-Rosemont), the meeting

Join Akron at ISCT 2018

Riding the commercial approvals of two CAR T immunotherapies last year, the energized regenerative medicine community will be coming together in Montreal for the Annual ISCT Global Meeting and Exhibition from Wednesday May 2nd through Saturday May 5th. Don’t miss Dr. Claudia Zylberberg, CEO of Akron Biotech, during the Quality & Operations Track speaking about

Innate Killer Summit 2018 presents cutting-edge innovations and the latest clinical data for NK cell therapies

Akron Biotech was proud to be a sponsor of this year’s Innate Killer Summit held in San Diego, California. The Innate Killer Summit is the leading, dedicated end-to-end meeting serving as a catalyst to ensure successful clinical and commercial translation of NK cell immunotherapies. The most current and advanced clinical data was presented as well